 Spironolactone
"Spironolactone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
| Descriptor ID |
D013148
|
| MeSH Number(s) |
D02.540.679 D04.808.745.745.855
|
| Concept/Terms |
Spiractin- Spiractin
- Alphapharm Brand of Spironolactone
Spirobeta- Spirobeta
- betapharm Brand of Spironolactone
Spirogamma- Spirogamma
- Wörwag Brand of Spironolactone
Spirono-Isis- Spirono-Isis
- Spirono Isis
- Alpharma Brand of Spironolactone
Spironone- Spironone
- Dexo Brand of Spironolactone
Spirospare- Spirospare
- Ashbourne Brand of Spironolactone
Verospiron- Verospiron
- Hormosan Brand of Spironolactone
Aldactone- Aldactone
- Roche Brand of Spironolactone
- Searle Brand of Spironolactone
- Pfizer Brand of Spironolactone
Aquareduct- Aquareduct
- Azupharma Brand of Spironolactone
duraspiron- duraspiron
- Merck dura Brand of Spironolactone
Flumach- Flumach
- Mayoly-Spindler Brand of Spironolactone
Frumikal- Frumikal
- Generosan Brand of Spironolactone
Jenaspiron- Jenaspiron
- Jenapharm Brand of Spironolactone
Novo-Spiroton- Novo-Spiroton
- Novo Spiroton
- NovoSpiroton
- Novopharm Brand of Spironolactone
Practon- Practon
- Cardel Brand of Spironolactone
spiro von ct- spiro von ct
- von ct, spiro
- ct-Arzneimittel Brand of Spironolactone
- ct Arzneimittel Brand of Spironolactone
|
Below are MeSH descriptors whose meaning is more general than "Spironolactone".
Below are MeSH descriptors whose meaning is more specific than "Spironolactone".
This graph shows the total number of publications written about "Spironolactone" by people in this website by year, and whether "Spironolactone" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 | | 2006 | 0 | 1 | 1 | | 2008 | 2 | 0 | 2 | | 2009 | 2 | 1 | 3 | | 2011 | 1 | 0 | 1 | | 2013 | 1 | 0 | 1 | | 2015 | 1 | 1 | 2 | | 2016 | 1 | 0 | 1 | | 2017 | 0 | 1 | 1 | | 2018 | 0 | 1 | 1 | | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Spironolactone" by people in Profiles.
-
Ali W, Bakris G. Evolution of Patiromer Use: a Review. Curr Cardiol Rep. 2020 07 09; 22(9):94.
-
Pitt B, Bakris GL, Weir MR, Freeman MW, Lainscak M, Mayo MR, Garza D, Zawadzki R, Berman L, Bushinsky DA. Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. ESC Heart Fail. 2018 08; 5(4):592-602.
-
Dojki FK, Bakris G. Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease. Curr Opin Nephrol Hypertens. 2017 09; 26(5):368-374.
-
Rossignol P, Girerd N, Bakris G, Vardeny O, Claggett B, McMurray JJV, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Spanyers S, Vincent J, Fay R, Lamiral Z, Solomon SD, Zannad F, Pitt B. Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. Eur J Heart Fail. 2017 06; 19(6):792-799.
-
Sternlicht H, Bakris GL. Spironolactone for resistant hypertension--hard to resist? Lancet. 2015 Nov 21; 386(10008):2032-2034.
-
Xu C, Tan S, Zhang J, Seubert CN, Gravenstein N, Sumners C, Vasilopoulos T, Martynyuk AE. Anesthesia with sevoflurane in neonatal rats: Developmental neuroendocrine abnormalities and alleviating effects of the corticosteroid and Cl(-) importer antagonists. Psychoneuroendocrinology. 2015 Oct; 60:173-81.
-
Mody KP, Lyons JJ, Jorde UP, Uriel N. A cold taken to heart. Circulation. 2015 May 12; 131(19):1703-11.
-
Tannenbaum S, Sayer GT. Advances in the pathophysiology and treatment of heart failure with preserved ejection fraction. Curr Opin Cardiol. 2015 May; 30(3):250-8.
-
Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail. 2014 Jan; 7(1):51-8.
-
Maron BA, Zhang YY, White K, Chan SY, Handy DE, Mahoney CE, Loscalzo J, Leopold JA. Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. Circulation. 2012 Aug 21; 126(8):963-74.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|